<DOC>
	<DOCNO>NCT00365170</DOCNO>
	<brief_summary>This trial conduct Europe , Middle East , North America South America . The aim trial compare use intensified insulin treatment insulin aspart ( NovoRapid® ) versus human insulin ( Actrapid® ) pregnancy .</brief_summary>
	<brief_title>Efficacy Safety Insulin Aspart vs. Human Insulin During Pregnancy Women With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 1 diabetes Treated insulin least 12 month Either plan become pregnant immediate future , willing undertake pre pregnancy counselling , screen HbA1c less equal 12.0 % , Pregnant normal singleton pregnancy , gestational age least 10 week time randomisation , confirm ultrasound scan . Previous birth child major congenital malformation More 2 previous multiple miscarriage stillbirths Severe hyperemesis gravidarum , require hospitalisation , accord Investigator judgement Subjects treat infertility Proliferative retinopathy maculopathy require acute treatment Drug alcohol abuse Impaired renal , hepatic cardiac function</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>